In the announcement below, the Juvenile Diabetes Research Foundation (JDRF) announced that it will provide Sernova $2.45 million to support a clinical trial at a major transplantation center in the United States. The purpose of the funding is to advance human clinical trials of Sernova’s novel cell macroencapsulated implantable and scalable Cell Pouch System (CPS) for patients with Severe Type 1 Diabetes and Hypoglycemia Unawareness. [Read more…]
The Ultimate Mesenchymal Stem Cell (MSC) Patent Analysis
A valuable metric to assess in order to quantify and qualify the nature of the global mesenchymal stem cell (MSC) market is the patent environment. Since the discovery of MSCs, a large and thriving research product market has grown into existence, largely because the cells are completely non-controversial and can be generated directly from adult cells. Today, the number of MSC products sold worldwide is increasing and it is clear that the cell type represents a lucrative product market.
Mesenchymal Stem Cell (MSC) Patent Landscape
To launch MSC products and technologies, one of the key areas to consider is the patent landscape for the cell type.
Therefore, this post explores the following attributes surrounding the MSC patent landscape: [Read more…]
Mesenchymal Stem Cell (MSC) Transplantation for Site-Specific Repair
Mesenchymal stem cells (MSCs) can be induced to differentiate and express the traits of a diverse range of cell types, including muscle, bone, skin, cartilage, tendons, ligaments, marrow stroma, fat, neural cells, and more. For this reason, MSCs represent a population of cells with the potential to contribute to treatments for a diverse range of acute and degenerative diseases in which tissues need regeneration or repair.
While mesenchymal stem cells have been explored for potential benefits across a wide range of conditions, there are four key areas that represent the majority of investigation to date, which are:
- Osteogenic repair
- Myogenic and myocardial repair
- Neural repair
- Pancreatic repair
Breaking Stem Cell News, Featuring Cynata, ORIG3N, Cellular Dynamics, Commence Bio, and More
This week stem cell industry participants announced major collaborations, patent awards, research advances, and more. Check out our stem cell industry coverage below and let me know what you think. Enjoy!
Interview with Paul Wotton, Current Board Member of Cynata Therapeutics and Previous President/CEO of Ocata Therapeutics
This is an exclusive interview with Dr. Paul Wotton, who joined Cynata Therapeutics (ASX: CYP) Board of Directors in June of 2016. Cynata is an Australian company that is developing a therapeutic stem cell platform technology originating from the University of Wisconsin-Madison that utilizes iPSCs are starting material for generating nearly unlimited quantities of MSCs. Dr. Wotton was previously President and CEO of Ocata Therapeutics, joining the company in July 2014 and managing it through an all-cash take-over by Atellas Pharma valued at $379 million.
ORIG3N and Kangstem Biotech Partner to Investigate Induced Neural Stem Cells for Disease Modeling
Boston biotech company ORIG3N has announced a collaboration with South Korea’s Kangstem Biotech in a joint effort to gain insight into the effectiveness of induced neural stem cells (iNSC) in disease modeling. As a pioneer of regenerative medicine, ORIG3N is leading the way towards the future of medicine by crowdsourcing blood samples to create the world’s largest and most diverse biorepository of stem cells. As part of this collaboration, Kangstem Biotech will be providing iNSC’s to ORIG3N for research.
CDI and National Eye Institute to Collaborate on iPSC-Derived Cell Therapies for Retinal Degenerative Disease
Cellular Dynamics International (CDI), a FUJIFILM company, announced that it has entered into a Cooperative Research and Development Agreement with the National Eye Institute, a division of the NIH, to conduct research to advance a cell transplantation therapy for the treatment of retinal degenerative disease using retinal pigment epithelium derived from induced pluripotent stem cells (iPSC-RPE). The collaboration includes the joint development of an optimized biocompatible biodegradable scaffold that is likely to be a critical component for a potential future therapy.
Commence Bio Receives 1st Patent for MSC1, An Innovative Cancer Immunotherapy Platform
Commence Bio announced that the company has received its first patent for MSC1.
Commence Bio is a pre-clinical stage biotechnology company that is based on the concept that cancer and other inflammatory conditions can be addressed by “rebooting patients’ immune systems” with a new class of medicinal stem cells, MSC1 and MSC2. The company is now developing a therapeutic pipeline, as well as offering research products that include MSC1 and MSC2 cells and media.
Do You Know the Top “Quality Guarantees” Among U.S. Cord Blood Banks?
A characteristic that can distinguish one cord blood bank from another is the amount of its quality guarantee. Currently, the top cord blood banks in the U.S offer quality guarantee packages that range from $25,000 – $90,000, with Americord topping that list at $90,000. Interestingly, Americord raised its guarantee from $80,000 to $90,000 in mid-2014 to further separate itself from the competition and increase its trustworthiness in the eyes of its clients. The primary reason for a cord blood bank to offer a quality guarantee is to reassure prospects that banking their children’s cord blood is a protected investment.
Mesenchymal Stem Cells – Advances & Applications [Global Strategic Report; 250 Pages]
As of July 2016, our highest-demand market report is “Mesenchymal Stem Cells – Advances & Applications.” You should view it because: 1) MSCs are one of the fastest growing areas of stem cell research, 2) MSCs are now more frequently cited than any other stem cell type within the scientific literature, and 3) Google Trend data shows MSC searches to be approximately twice as common as the next most common adult stem cell type. The market for MSCs is growing. Are you informed about market opportunities and ready to act on them now?
About BioInformant
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Why Has Utilization of Umbilical Cord Blood for Transplantation Declined?
In recent years, the rate of umbilical cord blood utilization has declined. To understand the dynamics behind this change, you need to understand cord blood registries and cord blood transplant statistics. Data about umbilical cord blood transplants from the donor registry of the CW Bill Young Cell Transplantation Program, including the National Cord Blood Inventory, are reported annually.[1]
The program’s donor registry, also called the Be The Match Registry®, is operated under Federal contracts by the National Marrow Donor Program® (NMDP).
The Be The Match Registry® is the world’s largest hematopoietic cell registry, listing more than 10.5 million individuals and approximately 185,000 cord blood units.[2]
Cord Blood Transplant Statistics | A Closer Look
In this article:
- The National Marrow Donor Program
- Bone Marrow Donors Worldwide
- The Cooperation of NMDP and BMDW
- The Decline in Utilization of Cord Blood for Transplantation Beginning in 2013
- Why Has Umbilical Cord Blood Transplantation Declined?
The National Marrow Donor Program
The National Marrow Donor Program is a contractor for the CW Bill Young Cell Transplantation Program operated through the U. S. Department of Health and Human Services, Health Resources and Services Administration, and Healthcare Systems Bureau. It is a non-profit organization launched in Minneapolis, MN, USA, in 1986.
Hematopoietic stem cell transplants from NMDP donors or umbilical cord blood units are used to treat patients with a variety of cancers and immune system conditions. To date, the NMDP had facilitated more than 55,000 transplants worldwide.[3]
Bone Marrow Donors Worldwide
Another group that exists is Bone Marrow Donors Worldwide (BMDW), an organization that coordinates the collection of the human leukocyte antigen (HLA) phenotypes of hematopoietic cell donors and cord blood units. BMDW participants currently include 48 cord blood banks from 32 countries worldwide.[4] Presently, more than 60,000 cord blood units are listed within its database.[5] This makes it the largest such database of its type in the world.
The Cooperation of NMDP and BMDW
The NMDP cooperates with BMDW in the Netherlands because BMDW coordinates communications between the world’s cord blood registries. Most national registries, including the NMDP’s Be The Match Registry®, have access to these worldwide volunteer donors, either through the BMDW or through individual terms and agreements.
Because of their wide reach, these organizations represent a method for assessing trends in cord blood banking storage and utilization, making them a valuable predictor of future trends. Specifically for this analysis, the CW Bill Young Cell Transplantation Program is used as a source of aggregated cord blood transplantation data.
Decline in Utilization of Cord Blood for Transplantation
Unfortunately, 2013 saw a decrease in the number of cord blood units used for transplant in the United States. In 2012, the CW Bill Young Cell Transplantation Program facilitated close to 1,200 transplants. In 2013, it facilitated approximately 1,100, a substantial year-over-year decline.[6] See the image below.
While the CW Bill Young Cell Transplantation Program did its last comprehensive analysis of registry data in 2014 using full-year 2013 data, it did release the following statement about FY 2014 data[7]:
“During 2014, cord blood units were used in 960 transplants. The National Cord Blood Inventory provided 544 cord blood units for these transplants.
Also, 1,225 transplants were performed using bone marrow and 4,068 transplants used peripheral blood stem cells.”
As mentioned previously, the registry facilitated close to 1,200 transplants in 2012, and approximately 1,100 in 2013.[8] Therefore, 2014 again experienced a decline in cord blood utilization relative to the prior year, and peripheral blood stem cells again saw an increase in utilization. This information has been incorporated into the graph above.
From conversations with industry experts and independent analysis, BioInformant believes this trend is continuing.
However, this trend is primarily localized to the United States and Europe. Within the UK, the country’s National Health System (NHS) has been working toward building an established volume of publicly donated cord blood units to have as a national inventory for medical purposes. Furthermore, in other countries around the world, including the UK, China, Japan, Taiwan, and France, there have been increases in cord blood transplant rates compared to prior years.
Therefore, the growth or decline in cord blood transplant rates is a geographically dependent variable.
Why Has Cord Blood Transplantation Declined?
All of the information so far is interesting, but the important question here is, “Why has umbilical cord blood transplantation declined?”
The major reason for declining cord blood transplants in recent years is the increasing utilization of peripheral blood stem cells as an alternative for HSCT.
A much lesser reason is that there was declining utilization of bone marrow as a source of stem cells for HSCT from 1998 to 2005, but that trend corrected from 2005 to 2013, with the utilization of bone marrow slightly increasing over that period.
These answers are visually represented by the graph below.
To learn more, view the “Global Cord Blood Banking Industry Report.“
What are your thoughts on cord blood transplant statistics and the decline in the utilization of umbilical cord blood for transplantation? Share them in the comments below.
Up Next: 38 Athletes Who Have Had Stem Cell Treatments
[1] “Donor Registry Transplant Data”. Home. [online] Available at: Bloodcell.transplant.hrsa.gov. [Accessed 24 Apr. 2016].
[2] Bethematch.org. Home. Available at: http://bethematch.org/ [Accessed 24 Apr. 2016].
[3] Ibid.
[4] Bmdw.org. BMDW: Home. Available at: http://bmdw.org/ [Accessed 25 Apr. 2016].
[5] Ibid.
[6] “Donor Registry Transplant Data”. Registry Data. Available at: http://bloodcell.transplant.hrsa.gov/research/transplant_data/registry_tx_data/index.html. 2016. [Accessed 24 Apr. 2016].
[7] “Blood Cell Transplantation”. Donor Registry Transplant Data. [online] Available at: http://bloodcell.transplant.hrsa.gov/ [Accessed 25 April 2016].
[8] Bloodcell.transplant.hrsa.gov, (2014). Donor Registry Transplant Data. [online] Available at: http://bloodcell.transplant.hrsa.gov/research/transplant_data/registry_tx_data/index.html [Accessed 25 April 2016].
- « Previous Page
- 1
- …
- 288
- 289
- 290
- 291
- 292
- …
- 336
- Next Page »